Call for Papers  

Article Details

Mini-Review Article

The Mechanisms of Current Platinum Anticancer Drug Resistance in the Glioma

[ Vol. 28 , Issue. 23 ]


Enzhou Lu, Ilgiz Gareev, Chao Yuan, Yanchao Liang, Jingxian Sun, Xin Chen, Ozal Beylerli, Albert Sufianov, Shiguang Zhao* and Guang Yang*   Pages 1863 - 1869 ( 7 )


Gliomas are the most common and malignant primary tumors of the central nervous system (CNS). Glioblastomas are the most malignant and aggressive form of primary brain tumors and account for the majority of brain tumor-related deaths. The current standard treatment for gliomas is surgical resection supplemented by postoperative chemotherapy. Platinum drugs are a class of chemotherapeutic drugs that affect the cell cycle, and the main site of action is the DNA of cells, which are common chemotherapeutic drugs in clinical practice. Chemotherapy with platinum drugs such as cisplatin, carboplatin, oxaliplatin, or a combination thereof is used to treat a variety of tumors. However, the results of gliomas chemotherapy are unsatisfactory, and resistance to platinum drugs is one of the important reasons. The resistance of gliomas to platinum drugs is the result of a combination of influencing factors. Decreased intracellular drug concentration, enhanced function of cell processing active products, enhanced repair ability of cellular DNA damage, and blockage of related apoptosis pathways play an important role in it. It is known that the pathogenic properties of glioma cells and the response of glioma towards platinum-based drugs are strongly influenced by non-coding RNAs, particularly, by microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). miRNAs and lncRNAs control drug sensitivity and the development of tumor resistance towards platinum drugs. This mini-review summarizes the resistance mechanisms of gliomas to platinum drugs, as well as molecules and therapies that can improve the sensitivity of gliomas to platinum drugs.


Glioma, platinum drugs, resistance mechanisms, chemosensitivity, prognosis, microRNAs, long non-coding RNAs.


Read Full-Text article